We have demonstrated for the first time that (a) CDDP down-regulates EGFR, activates p53 and increased ROS production in chemosensitive but not in chemoresistant NSCLC; (b) Akt confers resistance in NSCLC in part by activating EGFR and down-regulating p53 and ROS production; (c) p53 activation inhibits EGFR signaling and increased ROS production. This evidence concerns the gene TP53 and non-small cell lung carcinoma.